FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2055103764> ?p ?o ?g. }

• W2055103764 endingPage "1307" @default.
• W2055103764 startingPage "1304" @default.
• W2055103764 abstract "BackgroundThe aim of this study is to determine efficacy and feasibility of the combination regimen irinotecan and cisplatin in patients with cisplatin advanced penile cancer.Patients and methodsPatients with T3, T4, N1, N2, N3 or M1 cisplatin advanced penile cancer were treated with a combination of irinotecan (60 mg/m2) on days 1, 8 and 15 and cisplatin (80mg/m2) administered every 28 days. Patients were treated either in the neo-adjuvant setting for T3 or N1–N2 disease with a maximum of four cycles before surgery or up to eight cycles for T4 or N3 or M1 disease. The study was designed with the aim to exclude a response rate (complete response + partial response) <30% (α = 10%, power = 95%).ResultsTwenty-eight patients were included and evaluated for toxicity, and 26 eligible patients were evaluated for response. Toxicity was acceptable with three cases of grade 3 diarrhoea and two cases of grade 4 neutropenic fever. There were eight responses (two complete response and six partial response) (30.8%, 80% confidence interval 18.8% to 45.1%): three patients undergoing histological verification after chemotherapy had no evidence of malignancy.ConclusionThe study fails to demonstrate a response rate significantly >30%.The observation regarding M0 patients suggests to repeat this study in the neo-adjuvant setting." @default.
• W2055103764 created "2016-06-24" @default.
• W2055103764 creator A5006125841 @default.
• W2055103764 creator A5017847350 @default.
• W2055103764 creator A5038603211 @default.
• W2055103764 creator A5042784431 @default.
• W2055103764 creator A5043616693 @default.
• W2055103764 creator A5045667939 @default.
• W2055103764 creator A5059367996 @default.
• W2055103764 creator A5061157288 @default.
• W2055103764 creator A5082944210 @default.
• W2055103764 date "2008-07-01" @default.
• W2055103764 modified "2023-10-06" @default.
• W2055103764 title "A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992)" @default.
• W2055103764 cites W1592736385 @default.
• W2055103764 cites W1944693814 @default.
• W2055103764 cites W1967704797 @default.
• W2055103764 cites W2001058579 @default.
• W2055103764 cites W2005195199 @default.
• W2055103764 cites W2014415900 @default.
• W2055103764 cites W2017923598 @default.
• W2055103764 cites W2029409133 @default.
• W2055103764 cites W2052912631 @default.
• W2055103764 cites W2069649371 @default.
• W2055103764 cites W2081465700 @default.
• W2055103764 cites W2090069544 @default.
• W2055103764 cites W2102632609 @default.
• W2055103764 cites W2115725590 @default.
• W2055103764 cites W2123260800 @default.
• W2055103764 cites W2132747647 @default.
• W2055103764 cites W2139248078 @default.
• W2055103764 cites W2170568040 @default.
• W2055103764 cites W2176408375 @default.
• W2055103764 cites W2344721727 @default.
• W2055103764 cites W2408234065 @default.
• W2055103764 cites W2409244729 @default.
• W2055103764 cites W2416925668 @default.
• W2055103764 doi "https://doi.org/10.1093/annonc/mdn149" @default.
• W2055103764 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18417462" @default.
• W2055103764 hasPublicationYear "2008" @default.
• W2055103764 type Work @default.
• W2055103764 sameAs 2055103764 @default.
• W2055103764 citedByCount "103" @default.
• W2055103764 countsByYear W20551037642012 @default.
• W2055103764 countsByYear W20551037642013 @default.
• W2055103764 countsByYear W20551037642014 @default.
• W2055103764 countsByYear W20551037642015 @default.
• W2055103764 countsByYear W20551037642016 @default.
• W2055103764 countsByYear W20551037642017 @default.
• W2055103764 countsByYear W20551037642018 @default.
• W2055103764 countsByYear W20551037642019 @default.
• W2055103764 countsByYear W20551037642020 @default.
• W2055103764 countsByYear W20551037642021 @default.
• W2055103764 countsByYear W20551037642022 @default.
• W2055103764 countsByYear W20551037642023 @default.
• W2055103764 crossrefType "journal-article" @default.
• W2055103764 hasAuthorship W2055103764A5006125841 @default.
• W2055103764 hasAuthorship W2055103764A5017847350 @default.
• W2055103764 hasAuthorship W2055103764A5038603211 @default.
• W2055103764 hasAuthorship W2055103764A5042784431 @default.
• W2055103764 hasAuthorship W2055103764A5043616693 @default.
• W2055103764 hasAuthorship W2055103764A5045667939 @default.
• W2055103764 hasAuthorship W2055103764A5059367996 @default.
• W2055103764 hasAuthorship W2055103764A5061157288 @default.
• W2055103764 hasAuthorship W2055103764A5082944210 @default.
• W2055103764 hasBestOaLocation W20551037641 @default.
• W2055103764 hasConcept C121608353 @default.
• W2055103764 hasConcept C126322002 @default.
• W2055103764 hasConcept C126894567 @default.
• W2055103764 hasConcept C141071460 @default.
• W2055103764 hasConcept C143998085 @default.
• W2055103764 hasConcept C2776694085 @default.
• W2055103764 hasConcept C2777863537 @default.
• W2055103764 hasConcept C2778239845 @default.
• W2055103764 hasConcept C2780259306 @default.
• W2055103764 hasConcept C2781413609 @default.
• W2055103764 hasConcept C29730261 @default.
• W2055103764 hasConcept C31760486 @default.
• W2055103764 hasConcept C44249647 @default.
• W2055103764 hasConcept C526805850 @default.
• W2055103764 hasConcept C71924100 @default.
• W2055103764 hasConceptScore W2055103764C121608353 @default.
• W2055103764 hasConceptScore W2055103764C126322002 @default.
• W2055103764 hasConceptScore W2055103764C126894567 @default.
• W2055103764 hasConceptScore W2055103764C141071460 @default.
• W2055103764 hasConceptScore W2055103764C143998085 @default.
• W2055103764 hasConceptScore W2055103764C2776694085 @default.
• W2055103764 hasConceptScore W2055103764C2777863537 @default.
• W2055103764 hasConceptScore W2055103764C2778239845 @default.
• W2055103764 hasConceptScore W2055103764C2780259306 @default.
• W2055103764 hasConceptScore W2055103764C2781413609 @default.
• W2055103764 hasConceptScore W2055103764C29730261 @default.
• W2055103764 hasConceptScore W2055103764C31760486 @default.
• W2055103764 hasConceptScore W2055103764C44249647 @default.
• W2055103764 hasConceptScore W2055103764C526805850 @default.
• W2055103764 hasConceptScore W2055103764C71924100 @default.
• W2055103764 hasIssue "7" @default.
• W2055103764 hasLocation W20551037641 @default.

• next